메뉴 건너뛰기




Volumn 14, Issue 1, 2014, Pages

Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer

Author keywords

Axitinib; BLI; Bone metastasis; c MET; CRPC; VEGFR crizotinib; X ray; CT imaging

Indexed keywords

AXITINIB; CRIZOTINIB; SCATTER FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

EID: 84908091776     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-742     Document Type: Article
Times cited : (19)

References (49)
  • 1
    • 77955635233 scopus 로고    scopus 로고
    • Cancer statistics, 2010
    • 10.3322/caac.20073, 20610543
    • Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300. 10.3322/caac.20073, 20610543.
    • (2010) CA Cancer J Clin , vol.60 , Issue.5 , pp. 277-300
    • Jemal, A.1    Siegel, R.2    Xu, J.3    Ward, E.4
  • 2
    • 37549020086 scopus 로고    scopus 로고
    • Clinical practice. localized prostate cancer
    • 18160689
    • Walsh PC, DeWeese TL, Eisenberger MA. Clinical practice. localized prostate cancer. N Engl J Med 2007, 357(26):2696-2705. 10.1056/NEJMcp0706784, 18160689.
    • (2007) N Engl J Med , vol.357 , Issue.26 , pp. 2696-2705
    • Walsh, P.C.1    DeWeese, T.L.2    Eisenberger, M.A.3
  • 3
    • 33749345244 scopus 로고    scopus 로고
    • Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
    • 2360544, 16983403
    • Attard G, Sarker D, Reid A, Molife R, Parker C, de Bono JS. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br J Cancer 2006, 95(7):767-774. 10.1038/sj.bjc.6603223, 2360544, 16983403.
    • (2006) Br J Cancer , vol.95 , Issue.7 , pp. 767-774
    • Attard, G.1    Sarker, D.2    Reid, A.3    Molife, R.4    Parker, C.5    de Bono, J.S.6
  • 6
    • 78650305379 scopus 로고    scopus 로고
    • Treatment and prevention of bone complications from prostate cancer
    • 3010497, 20621630
    • Lee RJ, Saylor PJ, Smith MR. Treatment and prevention of bone complications from prostate cancer. Bone 2011, 48(1):88-95. 10.1016/j.bone.2010.05.038, 3010497, 20621630.
    • (2011) Bone , vol.48 , Issue.1 , pp. 88-95
    • Lee, R.J.1    Saylor, P.J.2    Smith, M.R.3
  • 7
    • 79958037582 scopus 로고    scopus 로고
    • Bone metastasis in prostate cancer: emerging therapeutic strategies
    • Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol 2011, 8(6):357-368.
    • (2011) Nat Rev Clin Oncol , vol.8 , Issue.6 , pp. 357-368
    • Sturge, J.1    Caley, M.P.2    Waxman, J.3
  • 8
    • 83255186301 scopus 로고    scopus 로고
    • Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib)
    • 22146228
    • Bowles DW, Kessler ER, Jimeno A. Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib). Drugs Today (Barc) 2011, 47(11):857-868. 10.1358/dot.2011.47.11.1688487, 22146228.
    • (2011) Drugs Today (Barc) , vol.47 , Issue.11 , pp. 857-868
    • Bowles, D.W.1    Kessler, E.R.2    Jimeno, A.3
  • 10
    • 0032818964 scopus 로고    scopus 로고
    • Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer
    • 10475365
    • Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, Freeman MR. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999, 54(3):523-527. 10.1016/S0090-4295(99)00167-3, 10475365.
    • (1999) Urology , vol.54 , Issue.3 , pp. 523-527
    • Duque, J.L.1    Loughlin, K.R.2    Adam, R.M.3    Kantoff, P.W.4    Zurakowski, D.5    Freeman, M.R.6
  • 11
    • 0027717345 scopus 로고
    • Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
    • 1887042, 7688183
    • Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993, 143(2):401-409. 1887042, 7688183.
    • (1993) Am J Pathol , vol.143 , Issue.2 , pp. 401-409
    • Weidner, N.1    Carroll, P.R.2    Flax, J.3    Blumenfeld, W.4    Folkman, J.5
  • 12
    • 80051552737 scopus 로고    scopus 로고
    • Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer
    • 21600762
    • Merino M, Pinto A, Gonzalez R, Espinosa E. Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer. Eur J Cancer 2011, 47(12):1846-1851. 10.1016/j.ejca.2011.04.020, 21600762.
    • (2011) Eur J Cancer , vol.47 , Issue.12 , pp. 1846-1851
    • Merino, M.1    Pinto, A.2    Gonzalez, R.3    Espinosa, E.4
  • 13
    • 0036192486 scopus 로고    scopus 로고
    • Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts
    • 11882460
    • Mayr-Wohlfart U, Waltenberger J, Hausser H, Kessler S, Gunther KP, Dehio C, Puhl W, Brenner RE. Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts. Bone 2002, 30(3):472-477. 10.1016/S8756-3282(01)00690-1, 11882460.
    • (2002) Bone , vol.30 , Issue.3 , pp. 472-477
    • Mayr-Wohlfart, U.1    Waltenberger, J.2    Hausser, H.3    Kessler, S.4    Gunther, K.P.5    Dehio, C.6    Puhl, W.7    Brenner, R.E.8
  • 14
    • 0028237788 scopus 로고
    • Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts
    • 8123039
    • Midy V, Plouet J. Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts. Biochem Biophys Res Commun 1994, 199(1):380-386. 10.1006/bbrc.1994.1240, 8123039.
    • (1994) Biochem Biophys Res Commun , vol.199 , Issue.1 , pp. 380-386
    • Midy, V.1    Plouet, J.2
  • 15
    • 10744225879 scopus 로고    scopus 로고
    • Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein
    • 14871830
    • Dai J, Kitagawa Y, Zhang J, Yao Z, Mizokami A, Cheng S, Nor J, McCauley LK, Taichman RS, Keller ET. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res 2004, 64(3):994-999. 10.1158/0008-5472.CAN-03-1382, 14871830.
    • (2004) Cancer Res , vol.64 , Issue.3 , pp. 994-999
    • Dai, J.1    Kitagawa, Y.2    Zhang, J.3    Yao, Z.4    Mizokami, A.5    Cheng, S.6    Nor, J.7    McCauley, L.K.8    Taichman, R.S.9    Keller, E.T.10
  • 16
    • 28244481510 scopus 로고    scopus 로고
    • Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity
    • 16322239
    • Kitagawa Y, Dai J, Zhang J, Keller JM, Nor J, Yao Z, Keller ET. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Res 2005, 65(23):10921-10929. 10.1158/0008-5472.CAN-05-1809, 16322239.
    • (2005) Cancer Res , vol.65 , Issue.23 , pp. 10921-10929
    • Kitagawa, Y.1    Dai, J.2    Zhang, J.3    Keller, J.M.4    Nor, J.5    Yao, Z.6    Keller, E.T.7
  • 17
    • 0036570938 scopus 로고    scopus 로고
    • Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for prostate cancer invasion
    • 11948964
    • van Leenders G, van Balken B, Aalders T, Hulsbergen-van de Kaa C, Ruiter D, Schalken J. Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for prostate cancer invasion. Prostate 2002, 51(2):98-107. 10.1002/pros.10073, 11948964.
    • (2002) Prostate , vol.51 , Issue.2 , pp. 98-107
    • van Leenders, G.1    van Balken, B.2    Aalders, T.3    Hulsbergen-van de Kaa, C.4    Ruiter, D.5    Schalken, J.6
  • 20
    • 84860330623 scopus 로고    scopus 로고
    • Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases
    • 21882211
    • Colombel M, Eaton CL, Hamdy F, Ricci E, van der Pluijm G, Cecchini M, Mege-Lechevallier F, Clezardin P, Thalmann G. Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases. Prostate 2012, 72(7):713-720. 10.1002/pros.21473, 21882211.
    • (2012) Prostate , vol.72 , Issue.7 , pp. 713-720
    • Colombel, M.1    Eaton, C.L.2    Hamdy, F.3    Ricci, E.4    van der Pluijm, G.5    Cecchini, M.6    Mege-Lechevallier, F.7    Clezardin, P.8    Thalmann, G.9
  • 22
    • 33847057016 scopus 로고    scopus 로고
    • The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression
    • 17283128
    • Verras M, Lee J, Xue H, Li TH, Wang Y, Sun Z. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res 2007, 67(3):967-975. 10.1158/0008-5472.CAN-06-3552, 17283128.
    • (2007) Cancer Res , vol.67 , Issue.3 , pp. 967-975
    • Verras, M.1    Lee, J.2    Xue, H.3    Li, T.H.4    Wang, Y.5    Sun, Z.6
  • 25
    • 60549088318 scopus 로고    scopus 로고
    • A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone
    • 2698812, 19176388
    • Li X, Loberg R, Liao J, Ying C, Snyder LA, Pienta KJ, McCauley LK. A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res 2009, 69(4):1685-1692. 10.1158/0008-5472.CAN-08-2164, 2698812, 19176388.
    • (2009) Cancer Res , vol.69 , Issue.4 , pp. 1685-1692
    • Li, X.1    Loberg, R.2    Liao, J.3    Ying, C.4    Snyder, L.A.5    Pienta, K.J.6    McCauley, L.K.7
  • 26
    • 79953272413 scopus 로고    scopus 로고
    • Pre-clinical mouse models of human prostate cancer and their utility in drug discovery
    • 3072580, 21483646, Chapter 14, Unit 14 15
    • Park SI, Kim SJ, McCauley LK, Gallick GE. Pre-clinical mouse models of human prostate cancer and their utility in drug discovery. Curr Protoc Pharmacol 2010, Chapter 14:Unit 14 15. 3072580, 21483646.
    • (2010) Curr Protoc Pharmacol
    • Park, S.I.1    Kim, S.J.2    McCauley, L.K.3    Gallick, G.E.4
  • 27
    • 0036604237 scopus 로고    scopus 로고
    • Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells
    • 11992617
    • Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate 2002, 52(1):20-33. 10.1002/pros.10091, 11992617.
    • (2002) Prostate , vol.52 , Issue.1 , pp. 20-33
    • Corey, E.1    Quinn, J.E.2    Bladou, F.3    Brown, L.G.4    Roudier, M.P.5    Brown, J.M.6    Buhler, K.R.7    Vessella, R.L.8
  • 28
    • 84872967522 scopus 로고    scopus 로고
    • Cancer statistics, 2013
    • 10.3322/caac.21166, 23335087
    • Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30. 10.3322/caac.21166, 23335087.
    • (2013) CA Cancer J Clin , vol.63 , Issue.1 , pp. 11-30
    • Siegel, R.1    Naishadham, D.2    Jemal, A.3
  • 29
    • 69249203584 scopus 로고    scopus 로고
    • Castration-resistant prostate cancer: from new pathophysiology to new treatment targets
    • 19560857
    • Chi KN, Bjartell A, Dearnaley D, Saad F, Schroder FH, Sternberg C, Tombal B, Visakorpi T. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol 2009, 56(4):594-605. 10.1016/j.eururo.2009.06.027, 19560857.
    • (2009) Eur Urol , vol.56 , Issue.4 , pp. 594-605
    • Chi, K.N.1    Bjartell, A.2    Dearnaley, D.3    Saad, F.4    Schroder, F.H.5    Sternberg, C.6    Tombal, B.7    Visakorpi, T.8
  • 31
    • 66149161780 scopus 로고    scopus 로고
    • Castration-resistant prostate cancer: locking up the molecular escape routes
    • 19447877
    • Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res 2009, 15(10):3251-3255. 10.1158/1078-0432.CCR-08-1171, 19447877.
    • (2009) Clin Cancer Res , vol.15 , Issue.10 , pp. 3251-3255
    • Attar, R.M.1    Takimoto, C.H.2    Gottardis, M.M.3
  • 32
    • 33644675811 scopus 로고    scopus 로고
    • Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis
    • 16278481
    • Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005, 23(32):8253-8261. 10.1200/JCO.2005.03.4777, 16278481.
    • (2005) J Clin Oncol , vol.23 , Issue.32 , pp. 8253-8261
    • Scher, H.I.1    Sawyers, C.L.2
  • 33
    • 0035010803 scopus 로고    scopus 로고
    • Metastatic bone disease: clinical features, pathophysiology and treatment strategies
    • 11417967
    • Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27(3):165-176. 10.1053/ctrv.2000.0210, 11417967.
    • (2001) Cancer Treat Rev , vol.27 , Issue.3 , pp. 165-176
    • Coleman, R.E.1
  • 34
    • 77949347731 scopus 로고    scopus 로고
    • Pathogenesis of osteoblastic bone metastases from prostate cancer
    • 20108337
    • Ibrahim T, Flamini E, Mercatali L, Sacanna E, Serra P, Amadori D. Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer 2010, 116(6):1406-1418. 10.1002/cncr.24896, 20108337.
    • (2010) Cancer , vol.116 , Issue.6 , pp. 1406-1418
    • Ibrahim, T.1    Flamini, E.2    Mercatali, L.3    Sacanna, E.4    Serra, P.5    Amadori, D.6
  • 35
    • 0041670903 scopus 로고    scopus 로고
    • Skeletal implications of prostate cancer
    • Bagi CM. Skeletal implications of prostate cancer. J Musculoskelet Neuronal Interact 2003, 3(2):112-117.
    • (2003) J Musculoskelet Neuronal Interact , vol.3 , Issue.2 , pp. 112-117
    • Bagi, C.M.1
  • 36
    • 11344267803 scopus 로고    scopus 로고
    • Prostate cancer bone metastases promote both osteolytic and osteoblastic activity
    • 14991763
    • Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 2004, 91(4):718-729. 10.1002/jcb.10662, 14991763.
    • (2004) J Cell Biochem , vol.91 , Issue.4 , pp. 718-729
    • Keller, E.T.1    Brown, J.2
  • 37
    • 11144237716 scopus 로고    scopus 로고
    • Osteoblasts in prostate cancer metastasis to bone
    • 15630412
    • Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005, 5(1):21-28. 10.1038/nrc1528, 15630412.
    • (2005) Nat Rev Cancer , vol.5 , Issue.1 , pp. 21-28
    • Logothetis, C.J.1    Lin, S.H.2
  • 38
    • 34548584066 scopus 로고    scopus 로고
    • Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer
    • 17262196
    • DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 2007, 15(7):869-876. 10.1007/s00520-006-0203-x, 17262196.
    • (2007) Support Care Cancer , vol.15 , Issue.7 , pp. 869-876
    • DePuy, V.1    Anstrom, K.J.2    Castel, L.D.3    Schulman, K.A.4    Weinfurt, K.P.5    Saad, F.6
  • 39
    • 43949146650 scopus 로고    scopus 로고
    • The cost of treating skeletal-related events in patients with prostate cancer
    • Lage MJ, Barber BL, Harrison DJ, Jun S. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008, 14(5):317-322.
    • (2008) Am J Manag Care , vol.14 , Issue.5 , pp. 317-322
    • Lage, M.J.1    Barber, B.L.2    Harrison, D.J.3    Jun, S.4
  • 40
    • 2942518111 scopus 로고    scopus 로고
    • Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
    • 15173273, Zoledronic Acid Prostate Cancer Study G
    • Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M, Zoledronic Acid Prostate Cancer Study G Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004, 96(11):879-882. 10.1093/jnci/djh141, 15173273, Zoledronic Acid Prostate Cancer Study G.
    • (2004) J Natl Cancer Inst , vol.96 , Issue.11 , pp. 879-882
    • Saad, F.1    Gleason, D.M.2    Murray, R.3    Tchekmedyian, S.4    Venner, P.5    Lacombe, L.6    Chin, J.L.7    Vinholes, J.J.8    Goas, J.A.9    Zheng, M.10
  • 41
    • 79952360832 scopus 로고    scopus 로고
    • Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
    • 3090685, 21353695
    • Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377(9768):813-822. 10.1016/S0140-6736(10)62344-6, 3090685, 21353695.
    • (2011) Lancet , vol.377 , Issue.9768 , pp. 813-822
    • Fizazi, K.1    Carducci, M.2    Smith, M.3    Damiao, R.4    Brown, J.5    Karsh, L.6    Milecki, P.7    Shore, N.8    Rader, M.9    Wang, H.10    Jiang, Q.11    Tadros, S.12    Dansey, R.13    Goessl, C.14
  • 45
    • 79960738374 scopus 로고    scopus 로고
    • Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer
    • 3146625, 21365123
    • Pfeiffer MJ, Smit FP, Sedelaar JP, Schalken JA. Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Mol Med 2011, 17(7-8):657-664. 3146625, 21365123.
    • (2011) Mol Med , vol.17 , Issue.7-8 , pp. 657-664
    • Pfeiffer, M.J.1    Smit, F.P.2    Sedelaar, J.P.3    Schalken, J.A.4
  • 46
    • 0029797701 scopus 로고    scopus 로고
    • Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro
    • 38800, 8755529
    • Grano M, Galimi F, Zambonin G, Colucci S, Cottone E, Zallone AZ, Comoglio PM. Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci U S A 1996, 93(15):7644-7648. 10.1073/pnas.93.15.7644, 38800, 8755529.
    • (1996) Proc Natl Acad Sci U S A , vol.93 , Issue.15 , pp. 7644-7648
    • Grano, M.1    Galimi, F.2    Zambonin, G.3    Colucci, S.4    Cottone, E.5    Zallone, A.Z.6    Comoglio, P.M.7
  • 47
    • 0029001626 scopus 로고
    • Hepatocyte growth factor is involved in formation of osteoclast-like cells mediated by clonal stromal cells (MC3T3-G2/PA6)
    • 7790391
    • Sato T, Hakeda Y, Yamaguchi Y, Mano H, Tezuka K, Matsumoto K, Nakamura T, Mori Y, Yoshizawa K, Sumitani K. Hepatocyte growth factor is involved in formation of osteoclast-like cells mediated by clonal stromal cells (MC3T3-G2/PA6). J Cell Physiol 1995, 164(1):197-204. 10.1002/jcp.1041640124, 7790391.
    • (1995) J Cell Physiol , vol.164 , Issue.1 , pp. 197-204
    • Sato, T.1    Hakeda, Y.2    Yamaguchi, Y.3    Mano, H.4    Tezuka, K.5    Matsumoto, K.6    Nakamura, T.7    Mori, Y.8    Yoshizawa, K.9    Sumitani, K.10
  • 48
    • 0034772250 scopus 로고    scopus 로고
    • Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480
    • Cancer, Leukemia Group B
    • George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ, Kantoff PW, Cancer, Leukemia Group B Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001, 7(7):1932-1936. Cancer, Leukemia Group B.
    • (2001) Clin Cancer Res , vol.7 , Issue.7 , pp. 1932-1936
    • George, D.J.1    Halabi, S.2    Shepard, T.F.3    Vogelzang, N.J.4    Hayes, D.F.5    Small, E.J.6    Kantoff, P.W.7
  • 49
    • 67651112022 scopus 로고    scopus 로고
    • Vascular endothelial growth factor regulates osteoblast survival - evidence for an autocrine feedback mechanism
    • 2701940, 19527527
    • Street J, Lenehan B. Vascular endothelial growth factor regulates osteoblast survival - evidence for an autocrine feedback mechanism. J Orthop Surg Res 2009, 4:19. 10.1186/1749-799X-4-19, 2701940, 19527527.
    • (2009) J Orthop Surg Res , vol.4 , pp. 19
    • Street, J.1    Lenehan, B.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.